INNOVIVA, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
INNOVIVA, INC. (INVA) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $213.92 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-19.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2020-02-19
- INNOVIVA, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-12-31 was $53.00M, a 1224.98% increase year-over-year.
- INNOVIVA, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-09-30 was $103.05M, a 524.55% increase year-over-year.
- INNOVIVA, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-06-30 was $30.00M, a 30.43% increase year-over-year.
- INNOVIVA, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-03-31 was $27.88M, a 12.55% decline year-over-year.
- INNOVIVA, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2019 was $213.92M, a 183.81% increase from fiscal 2018.
- INNOVIVA, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2018 was $75.38M, a 69.81% increase from fiscal 2017.
- INNOVIVA, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2017 was $44.39M, a 49.80% decline from fiscal 2016.
- INNOVIVA, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2016 was $88.42M, a 35.75% decline from fiscal 2015.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2019-12-31 | $53.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $156.05M derived: sum of 2 quarters · filed 2020-02-19 | $186.05M derived: sum of 3 quarters · filed 2020-02-19 | $213.92M 10-K · filed 2020-02-19 |
| 2019-09-30 | $103.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $133.05M derived: sum of 2 quarters · filed 2019-10-30 | $160.93M 10-Q · filed 2019-10-30 | $164.93M derived: sum of 4 quarters · filed 2020-02-19 |
| 2019-06-30 | $30.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $57.88M 10-Q · filed 2019-07-24 | $61.88M derived: sum of 3 quarters · filed 2020-02-19 | $78.38M derived: sum of 4 quarters · filed 2020-02-19 |
| 2019-03-31 | $27.88M 10-Q · filed 2019-05-01 | $31.88M derived: sum of 2 quarters · filed 2020-02-19 | $48.38M derived: sum of 3 quarters · filed 2020-02-19 | $71.38M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $20.50M derived: sum of 2 quarters · filed 2020-02-19 | $43.50M derived: sum of 3 quarters · filed 2020-02-19 | $75.38M 10-K · filed 2020-02-19 |
| 2018-09-30 | $16.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $39.50M derived: sum of 2 quarters · filed 2019-10-30 | $71.38M 10-Q · filed 2019-10-30 | $71.38M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $23.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $54.88M 10-Q · filed 2019-07-24 | $54.88M derived: sum of 3 quarters · filed 2020-02-19 | $62.88M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $31.88M 10-Q · filed 2019-05-01 | $31.88M derived: sum of 2 quarters · filed 2020-02-19 | $39.88M derived: sum of 3 quarters · filed 2020-02-19 | $49.88M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $8.00M derived: sum of 2 quarters · filed 2020-02-19 | $18.00M derived: sum of 3 quarters · filed 2020-02-19 | $44.39M 10-K · filed 2020-02-19 |
| 2017-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $18.00M derived: sum of 2 quarters · filed 2018-10-31 | $44.39M 10-Q · filed 2018-10-31 | $80.71M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $36.39M 10-Q · filed 2018-07-26 | $72.71M derived: sum of 3 quarters · filed 2019-02-19 | |
| 2017-03-31 | $26.39M 10-Q · filed 2018-05-04 | $62.71M derived: sum of 2 quarters · filed 2019-02-19 | ||
| 2016-12-31 | $36.32M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $88.42M 10-K · filed 2019-02-19 | ||
| 2016-09-30 | $52.10M 10-Q · filed 2017-11-03 | |||
| 2015-12-31 | $137.62M 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |